Geron (GERN) investor relations material

Company overview and key value drivers

• Transitioned to a commercial stage with RYTELO, the first telomerase inhibitor approved for lower-risk MDS, and expanding internationally.

• Focused on education, team enhancement, and financial discipline to drive successful commercialization and long-term growth.

• RYTELO uptake is increasing, with 33% of patients in front- and second-line settings, aiming for steady quarter-over-quarter growth.

• Educational efforts target both academic centers and community physicians, with digital and non-personal promotions to broaden reach.

• Organizational simplification and redeployment of resources have extended cash runway and improved operational efficiency.

Market dynamics and treatment paradigm

• Lower-risk MDS treatment has evolved from supportive care to ESAs, HMAs, and now RYTELO, which offers disease-modifying potential.

• RYTELO is positioned as a preferred second-line agent in NCCN guidelines, with unique efficacy in RS-negative and high EPO patients.

• Physicians are increasingly recognizing RYTELO’s broad applicability and durable response, especially in second-line settings.

• Real-world evidence confirms clinical trial results, supporting safety and efficacy across diverse patient populations.

• Duration of therapy in second-line mirrors clinical trials at about eight months, with later-line patients showing predictably shorter durations.

Commercial strategy and performance metrics

• Segmentation and messaging have been reset to focus on high-volume community physicians, who manage 80% of patients.

• Metrics tracked include demand growth, new account activation, and proportion of first- and second-line patient use.

• Internal rewards now emphasize second-line performance, aligning incentives with strategic goals.

• Educational initiatives at conferences and regional meetings are prioritized to drive awareness and adoption.

• Real-world data and ongoing education are expected to reinforce positive clinical outcomes and support revenue growth.